| European Federation of Internal Medicine

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News

Type: News Feed

Agenda - Challenges in drug development, regulation and clinical practice in immune thrombocytopenia

Submitted by Anonymous (not verified) on 5 June 2026 - 12:00

Agenda - Challenges in drug development, regulation and clinical practice in immune thrombocytopenia

Read more about Agenda - Challenges in drug development, regulation and clinical practice in immune thrombocytopenia

Human medicines European public assessment report (EPAR): CellCept, mycophenolate mofetil, Date of authorisation: 14/02/1996, Revision: 43, Status: Authorised

Submitted by Anonymous (not verified) on 5 June 2026 - 10:18

Human medicines European public assessment report (EPAR): CellCept, mycophenolate mofetil, Date of authorisation: 14/02/1996, Revision: 43, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): CellCept, mycophenolate mofetil, Date of authorisation: 14/02/1996, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): Tivdak, tisotumab vedotin, Date of authorisation: 28/03/2025, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 5 June 2026 - 9:31

Human medicines European public assessment report (EPAR): Tivdak, tisotumab vedotin, Date of authorisation: 28/03/2025, Revision: 4, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Tivdak, tisotumab vedotin, Date of authorisation: 28/03/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Opsumit, macitentan, Date of authorisation: 20/12/2013, Revision: 28, Status: Authorised

Submitted by Anonymous (not verified) on 5 June 2026 - 9:31

Human medicines European public assessment report (EPAR): Opsumit, macitentan, Date of authorisation: 20/12/2013, Revision: 28, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Opsumit, macitentan, Date of authorisation: 20/12/2013, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 14, Status: Authorised

Submitted by Anonymous (not verified) on 5 June 2026 - 9:23

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 14, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Insulin Aspart Injection, insulin aspart, Status: Application withdrawn

Submitted by Anonymous (not verified) on 5 June 2026 - 8:44

Human medicines European public assessment report (EPAR): Insulin Aspart Injection, insulin aspart, Status: Application withdrawn

Read more about Human medicines European public assessment report (EPAR): Insulin Aspart Injection, insulin aspart, Status: Application withdrawn

Appendix 1: Acceptable intakes established for N-nitrosamines

Submitted by Anonymous (not verified) on 5 June 2026 - 7:57

Appendix 1: Acceptable intakes established for N-nitrosamines

Read more about Appendix 1: Acceptable intakes established for N-nitrosamines

Timetable: Safety referral (Article 107i, urgent Union procedure)

Submitted by Anonymous (not verified) on 4 June 2026 - 16:45

Timetable: Safety referral (Article 107i, urgent Union procedure)

Read more about Timetable: Safety referral (Article 107i, urgent Union procedure)

Timetable: Safety referral (Article-20 and Article-31 pharmacovigilance)

Submitted by Anonymous (not verified) on 4 June 2026 - 16:45

Timetable: Safety referral (Article-20 and Article-31 pharmacovigilance)

Read more about Timetable: Safety referral (Article-20 and Article-31 pharmacovigilance)

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Agenda - Challenges in drug development, regulation and clinical practice in immune thrombocytopenia

Human medicines European public assessment report (EPAR): CellCept, mycophenolate mofetil, Date of authorisation: 14/02/1996, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): Tivdak, tisotumab vedotin, Date of authorisation: 28/03/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Opsumit, macitentan, Date of authorisation: 20/12/2013, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Insulin Aspart Injection, insulin aspart, Status: Application withdrawn

Appendix 1: Acceptable intakes established for N-nitrosamines

Timetable: Safety referral (Article 107i, urgent Union procedure)

Timetable: Safety referral (Article-20 and Article-31 pharmacovigilance)

Newsletters

Latest Newsletters

You are here

Newsletters

Latest Newsletters